Results 121 to 130 of about 108,288 (261)

Copy number variation analysis of cerebrospinal fluid metagenomic next‐generation sequencing data in assisting the diagnosis of pediatric brain tumors

open access: yes
Pediatric Investigation, EarlyView.
Changhong Ren   +7 more
wiley   +1 more source

Changing Aetiology of Perforated Peptic Ulcers: Rising Impact of Non‐Steroidal‐Anti‐Inflammatories in Western Australia

open access: yesANZ Journal of Surgery, EarlyView.
ABSTRACT Background Peptic ulcer disease (PUD) continues to be a health issue, mainly due to Helicobacter pylori (H. pylori) infection and non‐steroidal anti‐inflammatory drugs (NSAIDs). Despite better treatment of H. pylori and use of proton pump inhibitors, the rate of reduction in PUD complications is slowing down.
Vidya Willis   +3 more
wiley   +1 more source

Primary Diffuse large B-cell lymphoma of spleen: A rare case report

open access: yesMediterranean Journal of Hematology and Infectious Diseases, 2014
Primary splenic lymphoma is very rare with an incidence less than 1% and, 22% to 33% of the cases being diffuse large B-cell lymphoma with a relatively favourable prognosis.
Biswajit Dey   +5 more
doaj  

Machine learning‐driven investigation on liquid–liquid phase separation‐related prognostic signature in diffuse large B‐cell lymphoma

open access: yesBritish Journal of Haematology, EarlyView.
Summary Diffuse large B‐cell lymphoma (DLBCL) is the most common aggressive non‐Hodgkin lymphoma and is characterized by substantial heterogeneity. This study aimed to develop a liquid–liquid phase separation (LLPS)‐related prognostic model to improve risk stratification.
Zhen‐Zhong Zhou   +11 more
wiley   +1 more source

Primary Diffuse Large Cell Lymphoma of the Bladder: Case Report and Literature Review

open access: yesMiddle East Journal of Cancer, 2017
Most bladder tumors are epithelial in origin. Nonepithelial cancers are rarely located in the bladder. Sarcomas are the most common malignancies among nonepithelial cancers. Primary bladder lymphoma is rare and mostly low grade. Here, we have reported
Mansour Ansari   +8 more
doaj  

Metabolic heterogeneity‐based radiomic model predicts treatment outcomes of primary mediastinal B‐cell lymphoma patients in the IELSG37 study

open access: yesBritish Journal of Haematology, EarlyView.
Summary Early identification of patients at risk of failing first‐line therapy remains a key challenge in primary mediastinal B‐cell lymphoma (PMBCL). This study assessed whether positron emission tomography (PET) radiomics could predict treatment outcomes in PMBCL.
L. Ceriani   +10 more
wiley   +1 more source

Diffuse Large B-cell Lymphoma of the Testis [PDF]

open access: yesMayo Clinic Proceedings, 2016
Rosalind F, Sandell, Lori A, Erickson
openaire   +2 more sources

Minimal residual disease in diffuse large B‐cell lymphoma after first‐line therapy: Defining the continuum from metabolic remission to molecular clearance

open access: yesBritish Journal of Haematology, EarlyView.
Summary Response assessment in diffuse large B‐cell lymphoma (DLBCL) has traditionally relied on anatomical and metabolic imaging, with fluorodeoxyglucose positron emission tomography (FDG‐PET)–defined complete metabolic remission representing the principal end‐point of first‐line therapy. However, growing evidence indicates that metabolic control does
Santino Caserta   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy